Key facts
- This page summarizes Jatin Markand Patel's Form 3 filing for BioXcel Therapeutics, Inc. (BTAI).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Apr 2023, 19:14.
Jatin Markand Patel - 03 Apr 2023 Form 3 Insider Report for BioXcel Therapeutics, Inc. (BTAI)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- BTAI
- Reported as of
- 03 Apr 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/Jatin Patel
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Jatin Markand Patel filed Form 3 for BioXcel Therapeutics, Inc. (BTAI) on 13 Apr 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BTAI
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,546,750
- Date
- 03 Apr 2023
- Ownership
- By BioXcel LLC
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BTAI
holding
Derivative
BTAI Aug 18 2023 $25 Put
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 03 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001 per share
- Underlying amount
- 1,000
- Exercise price
- $25.00
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
The Reporting Person may be deemed to share investment control over shares of Common Stock of the Issuer held by BioXcel LLC and held indirectly by BioXcel Holdings, Inc. The reporting person disclaims beneficial ownership of the reported securities except to the extent, if any, of the reporting person's pecuniary interest therein, and this filing shall not be deemed an admission that the Reporting Person is, for purposes of Section 16 of the Securities Exchange Act or otherwise, the beneficial owner of any such shares of Common Stock.